In this article, we will discuss Acalabrutinib (1). So, let’s get started.
Class of Medication:
Acalabrutinib belongs to a class of medications known as Bruton’s tyrosine kinase (BTK) inhibitors. BTK is a protein that plays a role in the development and survival of B cells, which are a type of white blood cell.
Indications:
Acalabrutinib is primarily used for the treatment of specific types of blood cancers, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Mantle Cell Lymphoma (MCL):
Acalabrutinib is approved for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. MCL is a type of non-Hodgkin lymphoma that usually affects older adults.
Chronic Lymphocytic Leukemia (CLL):
Acalabrutinib is also indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may be used as a first-line treatment or in patients who have received prior therapies.
Mechanism of Action:
Acalabrutinib works by inhibiting Bruton’s tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway. By blocking BTK, acalabrutinib interferes with the survival and proliferation of cancerous B cells.